Samuraciclib (CDK7i)
HR+, HER2- Advanced Breast Cancer
Key Facts
About Carrick Therapeutics
Carrick Therapeutics is an Ireland-founded, clinical-stage oncology biotech with a strategic shift to a Boston headquarters, indicating a focus on the U.S. biopharma ecosystem. Its lead asset, samuraciclib (a CDK7 inhibitor), is in multiple Phase 2 trials for HR+/HER2- advanced breast cancer, showing a combination-focused development strategy. The company also has an early-stage, first-in-class CDK12/13 inhibitor, CT7439, in Phase 1, diversifying its pipeline. Carrick operates as a private company, collaborating with major pharma partners to advance its programs.
View full company profileAbout Carrick Therapeutics
Carrick Therapeutics is an Ireland-founded, clinical-stage oncology biotech with a strategic shift to a Boston headquarters, indicating a focus on the U.S. biopharma ecosystem. Its lead asset, samuraciclib (a CDK7 inhibitor), is in multiple Phase 2 trials for HR+/HER2- advanced breast cancer, showing a combination-focused development strategy. The company also has an early-stage, first-in-class CDK12/13 inhibitor, CT7439, in Phase 1, diversifying its pipeline. Carrick operates as a private company, collaborating with major pharma partners to advance its programs.
View full company profileAbout Carrick Therapeutics
Carrick Therapeutics is an Ireland-founded, clinical-stage oncology biotech with a strategic shift to a Boston headquarters, indicating a focus on the U.S. biopharma ecosystem. Its lead asset, samuraciclib (a CDK7 inhibitor), is in multiple Phase 2 trials for HR+/HER2- advanced breast cancer, showing a combination-focused development strategy. The company also has an early-stage, first-in-class CDK12/13 inhibitor, CT7439, in Phase 1, diversifying its pipeline. Carrick operates as a private company, collaborating with major pharma partners to advance its programs.
View full company profile